Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gastroparesis
Biotech
Vanda’s CEO pens searing letter to FDA’s Califf after rejection
After receiving an FDA rejection last fall, Vanda CEO Mihael Polymeropoulos is criticizing the agency's “disturbing pattern of conduct."
Gabrielle Masson
Jan 9, 2025 10:51am
Vanda receives FDA rejection, issues fiery response
Sep 19, 2024 8:02am
Neurogastrx bags $60M to join crowded gastrointestinal field
Aug 26, 2021 6:30am
Neurogastrx reels in $45M series A for gastroparesis med
Jan 5, 2018 11:11am
UPDATED: Allergan pays $200M+ for GI candidate on PhIIb data
Oct 27, 2016 9:49am
Single-asset biotech Altos gains Takeda R&D backing
Jul 1, 2016 8:57am
